Business
Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor
"I am pleased to share this important new data on RVX-208 "apabetalone" as we embark on our...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\"I am pleased to share this important new data on RVX-208 \"apabetalone\" as we embark on our Phase 3 clinical trial BETonMACE,\" – Dr. Norman Wong\n\n\n\nLONDON, UK and CALGARY, Aug. 31, 2015 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) is pleased to announce that Dr. Norman Wong, chief scientific officer of Resverlogix Corp. presented new data at the European Society of Cardiology (ESC) Congress 2015 in a poster presentation titled: \"RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-I/HDL.\" \n\nThe presentation summarizes studies designed to further understand the reductions in major adverse cardiovascular events (MACE) observed in patients with atherosclerotic disease given RVX-208 from the phase 2b trials called SUSTAIN and ASSURE. In order to identify the potential biologic processes underlying the benefit of RVX-208 in the study patients, primary human hepatocytes were exposed to RVX-208 and then changes in gene expression were surveyed using micro-array technology. This treatment caused decreases in the expression of many genes involved in cholesterol synthesis, fatty acid synthesis, innate immunity and glucose processing. Amongst the changes observed, RVX-208 decreased expression in 19 out of 26 genes that encoded components in the complement pathway. Similarly, RVX-208 decreased expression in 20 out of 33 gene that encoded components within the coagulation cascade. Further support of the micro-array data that identified changes in gene expression by probing the messenger RNA (mRNA) levels was pursued by measuring specific proteins within the complement and coagulation cascade using plasma from SUSTAIN and ASSURE trials. Results showed significant decreases ranging from 7-12% vs. baseline in complement (i.e. complement factor 3) and coagulation components. In additional studies, donor whole blood was exposed ex-vivo to RVX-208 followed by micro-array analysis enabling the identification of several pathways with known roles in atherogenesis including; pro-inflammatory signaling, cell-cell interactions and extracellular matrix organization. The actions of RVX-208 lowered atherogenesis by downregulating (8 of 11) pro-atherogenic genes but in contrast, upregulated (5 of 7) anti-atherogenic genes that control monocyte recruitment, mig...